Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial

Mozaffarian, 2015, Heart disease and stroke statistics--2015 update: a report from the American Heart Association, Circulation, 131, e29 Mehta, 2016, Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association, Circulation, 133, 916, 10.1161/CIR.0000000000000351 Akhter, 2009, Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR), Am Heart J, 157, 141, 10.1016/j.ahj.2008.08.012 Lansky, 2009, Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial), Am J Cardiol, 103, 1196, 10.1016/j.amjcard.2009.01.030 Barrett-Connor, 1991, Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study, JAMA, 265, 627, 10.1001/jama.1991.03460050081025 Kawamoto, 2016, Acute Coronary Syndromes: Differences in Men and Women, Curr Atherosclerosis Rep, 18, 73, 10.1007/s11883-016-0629-7 Mosca, 2011, Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes, Circulation, 124, 2145, 10.1161/CIRCULATIONAHA.110.968792 Blomkalns, 2005, J Am Coll Cardiol, 45, 832, 10.1016/j.jacc.2004.11.055 Koopman, 2013, Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010, Eur Heart J, 34, 3198, 10.1093/eurheartj/eht368 Packer, 2022, Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis, Circulation, 146, 1383, 10.1161/CIRCULATIONAHA.122.061732 Santos-Gallego, 2019, Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics, J Am Coll Cardiol, 73, 1931, 10.1016/j.jacc.2019.01.056 Santos-Gallego, 2021, Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction, J Am Coll Cardiol, 77, 243, 10.1016/j.jacc.2020.11.008 Requena-Ibanez, 2022, Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial, Diabetes Metabol Syndr, 16, 102417, 10.1016/j.dsx.2022.102417 McMurray, 2019, Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction, N Engl J Med, 381, 1995, 10.1056/NEJMoa1911303 Packer, 2020, Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure, N Engl J Med, 383, 1413, 10.1056/NEJMoa2022190 Anker, 2021, Empagliflozin in Heart Failure with a Preserved Ejection Fraction, N Engl J Med, 385, 1451, 10.1056/NEJMoa2107038 Butler, 2022, Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction, Circulation, 146, 1046, 10.1161/CIRCULATIONAHA.122.059755 Solomon, 2022, Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction, N Engl J Med, 387, 1089, 10.1056/NEJMoa2206286 Wang, 2022, Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER, Circulation, 147, 624, 10.1161/CIRCULATIONAHA.122.062832 von Lewinski, 2022, Empagliflozin in acute myocardial infarction: the EMMY trial, Eur Heart J, 43, 4421, 10.1093/eurheartj/ehac494 Tripolt, 2020, Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial, Am Heart J, 221, 39, 10.1016/j.ahj.2019.12.004 Myhre, 2022, Sex and Race Differences in N-Terminal Pro-B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the Community, JAMA Cardiol, 7, 623, 10.1001/jamacardio.2022.0680 Lam, 2011, Influence of sex and hormone status on circulating natriuretic peptides, J Am Coll Cardiol, 58, 618, 10.1016/j.jacc.2011.03.042 Gardin, 1995, Sex, age, and disease affect echocardiographic left ventricular mass and systolic function in the free-living elderly. The Cardiovascular Health Study, Circulation, 91, 1739, 10.1161/01.CIR.91.6.1739 Vergaro, 2021, NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories, JACC Heart Fail, 9, 653, 10.1016/j.jchf.2021.05.014 O’Donoghue, 2021, The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus, Diabetologia, 64, 1226, 10.1007/s00125-021-05399-2 Zinman, 2018, Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME(R), Diabetologia, 61, 1522, 10.1007/s00125-018-4630-2 Daitch, 2022, Underrepresentation of women in randomized controlled trials: a systematic review and meta-analysis, Trials, 23, 1038, 10.1186/s13063-022-07004-2 Dadashova, 2016, Gender differences of response to various options of drug therapy in patients with chronic heart failure after suffered myocardial infarction, Kazan Medical Journal, 97, 17, 10.17750/KMJ2016-17 Lee, 2019, Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome, J Am Coll Cardiol, 74, 2032, 10.1016/j.jacc.2019.07.082 Jin, 2020, Women’s Participation in Cardiovascular Clinical Trials From 2010 to 2017, Circulation, 141, 540, 10.1161/CIRCULATIONAHA.119.043594 Ding, 2007, Sex differences in perceived risks, distrust, and willingness to participate in clinical trials: a randomized study of cardiovascular prevention trials, Arch Intern Med, 167, 905, 10.1001/archinte.167.9.905 Peterson, 2004, Willingness to participate in cardiac trials, Am J Geriatr Cardiol, 13, 11, 10.1111/j.1076-7460.2004.01709.x